🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

41 results for “ALX” Clear

  1. Alxn1920 placebo product, ALXN1920

    Alexion Europe SAS

    Primary Mebranous Nephropathy (PMN)

    phase 2 small molecule active

    1 trial

  2. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  3. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial

  4. Pembrolizumab

    ALX ONCOLOGY HOLDINGS INC

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  5. Rapamune 1 mg/mL oral solution, Rapamune 0.5 mg coated tablets, Co-Trimoxazole Forte 160/800mg Tablets, Rapamune 2 mg coated tablets, adeno-associated virus, serotype 9 (AAV9), PREDNISONE VIATRIS 5 mg, comprimé sécable, PREDNISONE VIATRIS 1 mg, comprimé, PREDNISONE VIATRIS 20 mg, comprimé sécable, Prednisone Olikla 2.5 mg tablety, Prednisone Olikla 10 mg tablety, Prednisone Olikla 50 mg tablety, Rapamune 1 mg coated tablets

    Alexion Europe SAS

    BAG3 Mutation Associated Dilated Cardiomyopathy

    phase 2 small molecule active

    1 trial

  6. Tarperprumig Placebo, Tarperprumig

    Alexion Europe SAS

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

    phase 2 small molecule active

    1 trial

  7. Teduglutide (ALX-0600)

    Takeda Pharmaceuticals International AG

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  8. Ultomiris 300 mg/30 mL concentrate for solution for infusion, Concentrate for solution for infusion

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  9. Vialed Saline Placebo, ALXN2030

    Alexion Europe SAS

    Antibody-Mediated Rejection after Kidney Transplantation

    phase 2 small molecule active

    1 trial

  10. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial

  11. Zanidatamab

    ALX ONCOLOGY HOLDINGS INC

    HER2-expressing Cancers

    phase 2 small molecule completed

    1 trial

  12. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Head and Neck Cancer

    phase 2 small molecule active

    2 trials

  13. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  14. Evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Bladder Cancer

    phase 1 small molecule completed

    1 trial

  15. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  16. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Higher Risk Myelodysplastic Syndromes

    phase 1 small molecule terminated

    1 trial

  17. evorpacept

    ALX ONCOLOGY HOLDINGS INC

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources